# Gyre Therapeutics Posts $32.9 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/51300
Published: 2026-11-08T02:48:32.000Z
Updated: 2026-11-08T02:48:32.000Z
Section: Business

> Revenue rose 0.6% year over year, and the company maintained its 2026 revenue guidance at $100.5 million to $111 million.

Gyre Therapeutics, Inc. posted $32.9 million in third-quarter revenue, up 0.6% from a year earlier, and recorded a GAAP loss per share of $0.04.

The company maintained its 2026 revenue guidance at $100.5 million to $111 million.